PRNewsWire
26 Oct 2026, 21:52 UTC · 55m ago
AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS
Impact · against what's priced in
The appointment of David W. Gibbs to Amgen's board is not a material catalyst for the stock price. While his expertise in consumer brands may assist with future launch strategies, the market's valuation currently hinges on clinical and manufacturing outcomes for MariTide rather than board composition.
- AMGN+0.00
Doesn't touch the price's assumptions
- The price assumes
Whether MariTide's phase 3 program and manufacturing build-out can deliver the growth the reverse-DCF requires
The appointment of a former Yum! Brands CEO to improve patient acquisition for 2027 launches does not address the core valuation drivers, specifically the phase 3 results and manufacturing scale of the MariTide obesity candidate.
What AMGN's price assumes · Sep 12
Top 1 mover · tap to explore
